Drug Approvals
🌏 NMPA Page 8NMPA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.
Showing 85–96 of 97 articles
FDA Approves Auvelity for MDD: A New Antidepressant Option
Apotex Receives First Canadian Health Canada Approval for Generic Ozempic (Semaglutide) Alternative
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
Energenesis Biomedical ENERGI-F703DFU Diabetic Foot Ulcer Treatment Data to Be Presented at EWMA 2026
Newleos Begins Phase 1b Trial of NTX-2001 for Alcohol Use Disorder Treatment
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China
PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals
Methylphenidate Shortage Update: Concerta and Ritalin LA Supply Restored, Rubifen LA Expected by June 2026
NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals
NMPA Approval Oncology Drugs: Accelerated & Conditional Pathways Explained
Corcept Therapeutics Faces FDA Rejection of Relacorilant for Cushing's Syndrome, Investor Lawsuit Filed